Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 177, Issue 9, 2008, Pages 995-1001

  Tunney, Michael M ^a   Field, Tyler R ^a   Moriarty, Thomas F ^a   Patrick, Sheila ^a   Doering, Gerd ^b   Muhlebach, Marianne S ^c   Wolfgang, Matthew C ^c   Boucher, Richard ^c   Gilpin, Deirdre F ^a   McDowell, Andrew ^a   Elborn, J Stuart ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Anaerobe; Cystic fibrosis; Infection; Pathogenesis

Indexed keywords

AMPICILLIN; AZITHROMYCIN; AZTREONAM; CEFTAZIDIME; CLINDAMYCIN; COLISTIN; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ACHROMOBACTER XYLOSOXIDANS; ACTINOMYCES; ADULT; ANAEROBIC BACTERIUM; ANTIBIOTIC SENSITIVITY; ARTICLE; BACILLUS; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BIFIDOBACTERIUM; BULLEIDIA; BURKHOLDERIA CEPACIA; CHILD; CLOSTRIDIUM; CONTROLLED STUDY; CYSTIC FIBROSIS; ESCHERICHIA COLI; FUSOBACTERIUM; GEMELLA; HUMAN; LACTOBACILLUS; LUNG INFECTION; LUNG LAVAGE; MAJOR CLINICAL STUDY; MICROCOCCUS; MONOTHERAPY; NEISSERIA; PEPTOSTREPTOCOCCUS; PREVOTELLA; PRIORITY JOURNAL; PROPIONIBACTERIUM; PSEUDOMONAS AERUGINOSA; ROTHIA; SPUTUM ANALYSIS; STAPHYLOCOCCUS; STENOTROPHOMONAS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS; VEILLONELLA; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; FORCED EXPIRATORY VOLUME; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; RISK FACTOR; SPUTUM;

ADOLESCENT; ADULT; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; BACTERIOLOGICAL TECHNIQUES; BRONCHOALVEOLAR LAVAGE FLUID; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FORCED EXPIRATORY VOLUME; HUMANS; MIDDLE AGED; RISK FACTORS; SPUTUM;

EID: 42949105490     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200708-1151OC     Document Type: Article

References (55)

1. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007;29:522-526.
2. Ratjen F. Changes in strategies for optimal antibacterial therapy in cystic fibrosis. Int J Antimicrob Agents 2001;17:93-96.
3. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002;109:317-325.
4. Yoon SS, Hennigan RF, Hilliard GM, Ochsner UA, Parvatiyar K, Kamani MC, Allen HL, DeKievit TR, Gardner PR, Schwab U, et al. Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev Cell 2002;3:593-603.
5. Brook I, Fink R. Transtracheal aspiration in pulmonary infection in children with cystic fibrosis. Eur J Respir Dis 1983;64:51-57.
6. Thomassen MJ, Klinger JD, Badger SJ, van Heeckeren DW, Stern RC. Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis. J Pediatr 1984;104:352-356.
7. Jewes LA, Spencer RC. The incidence of anaerobes in the sputum of patients with cystic fibrosis. J Med Microbiol 1990;31:271-274.
8. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Bruce KD. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 2004;42:5176-5183.
9. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Kehagia V, Jones GR, Bruce KD. Bacterial activity in cystic fibrosis lung infections. Respir Res 2005;6:49.
10. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Kehagia V, Connett GJ, Bruce KD. Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. J Clin Microbiol 2006;44:2601-2604.
11. Dore P, Robert R, Grollier G, Rouffineau J, Lanquetot H, Charriere JM, Fauchere JL. Incidence of anaerobes in ventilator-associated pneumonia with use of a protected specimen brush. Am J Respir Crit Care Med 1996;153:1292-1298.
12. Robert R, Grollier G, Frat JP, Godet C, Adoun M, Fauchere JL, Dore P. Colonization of lower respiratory tract with anaerobic bacteria in mechanically ventilated patients. Intensive Care Med 2003;29:1062-1068.
13. Mori T, Ebe T, Takahashi M, Isonuma H, Ikemoto H, Oguri T. Lung abscess: analysis of 66 cases from 1979 to 1991. Intern Med 1993;32:278-284.
14. Hammond JM, Potgieter PD, Hanslo D, Scott H, Roditi D. The etiology and antimicrobial susceptibility patterns of microorganisms in acute community-acquired lung abscess. Chest 1995;108:937-941.
15. Brook I, Frazier EH. Aerobic and anaerobic microbiology of empyema: a retrospective review in two military hospitals. Chest 1993;103:1502-1507.
16. Field TR, McDowell A, Patrick S, Elborn JS, Tunney MM. Use of anaerobic bacteriological culture for the detection of anaerobic bacteria in sputum from cystic fibrosis patients. J Cyst Fibros 2006;5:S15.
17. Tunney M, Field TR, McDowell A, Patrick S, Elborn JS. Isolation and identification of anaerobic bacteria from the sputum of cystic fibrosis patients [abstract]. Ped Pulmonol 2006;41(Suppl 29):326.
18. Muhlebach MS, Stewart PW, Leigh MW, Noah TL. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999;160:186-191.
19. Muhlebach MS, Miller MB, Moore C, Wedd JP, Drake AF, Leigh MW. Are lower airway or throat cultures predictive of sinus bacteriology in cystic fibrosis? Pediatr Pulmonol 2006;41:445-451.
20. Xu J, Moore JE, Murphy PG, Millar BC, Redmond AO, Elborn JS. Molecular (PCR) detection of Pseudomonas spp. other than P. aeruginosa directly from the sputum of adults and children with cystic fibrosis. Br J Biomed Sci 2004;61:147-149.
21. LiPuma JJ, Dulaney BJ, McMenamin JD, Whitby PW, Stull TL, Coenye T, Vandamme P. Development of rRNA-based PCR assays for identification of Burkholderia cepacia complex isolates recovered from cystic fibrosis patients. J Clin Microbiol 1999;37:3167-3170.
22. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, 7th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2007. CLSI Document No. M11-A7.
23. Evans CA, Mattern KL. Individual differences in the bacterial flora of the skin of the forehead: Peptococcus saccharolyticus. J Invest Dermatol 1978;71:152-153.
24. Westblom TU, Gorse GJ, Milligan TW, Schindzielorz AH. Anaerobic endocarditis caused by Staphylococcus saccharolyticus. J Clin Microbiol 1990;28:2818-2819.
25. Harris JK, De Groote MA, Sagel SD, Zemanick ET, Kapsner R, Penvari C, Kaess H, Deterding RR, Accurso FJ, Pace NR. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci USA 2007;104:20529-20533.
26. Aas JA, Paster BJ, Stokes LN, Olsen I, Dewhirst FE. Defining the normal bacterial flora of the oral cavity. J Clin Microbiol 2005;43:5721-5732.
27. Verma P. Laboratory diagnosis of anaerobic pleuropulmonary infections. Semin Respir Infect 2000;15:114-118.
28. Kim EJ, Wang W, Deckwer WD, Zeng AP. Expression of the quorum-sensing regulatory protein LasR is strongly affected by iron and oxygen concentrations in cultures of Pseudomonas aeruginosa irrespective of cell density. Microbiology 2005;151:1127-1138.
29. Sibley CD, Rabin H, Surette MG. Cystic fibrosis: a polymicrobial infectious disease. Future Microbiol 2006;1:53-61.
30. Duan K, Dammel C, Stein J, Rabin H, Surette MG. Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication. Mol Microbiol 2003;50:1477-1491.
31. Barksdale L. Identifying Rothia dentocariosa. Ann Intern Med 1979;91:786-788.
32. Salamon SA, Prag J. Three cases of Rothia dentocariosa bacteraemia: frequency in Denmark and a review. Scand J Infect Dis 2002;34:153-157.
33. Boudewijns M, Magerman K, Verhaegen J, Debrock G, Peetermans WE, Donkersloot P, Mewis A, Peeters V, Rummens JL, Cartuyvels R. Rothia dentocariosa, endocarditis and mycotic aneurysms: case report and review of the literature. Clin Microbiol Infect 2003;9:222-229.
34. Shreve MR, Butler S, Kaplowitz HJ, Rabin HR, Stokes D, Light M, Regelmann WE. Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis. J Clin Microbiol 1999;37:753-757.
35. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax 2007;62:360-367.
36. Baughman RP, Keeton DA, Perez C, Wilmott RW. Use of bronchoalveolar lavage semiquantitative cultures in cystic fibrosis. Am J Respir Crit Care Med 1997;156:286-291.
37. Rosenfeld M, Gibson R, McNamara S, Emerson J, McCoyd KS, Shell R, Borowitz D, Konstan MW, Retsch-Bogart G, Wilmott RW, et al. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J Pediatr 2001;139:572-577.
38. McGarvey LP, Dunbar K, Martin SL, Brown V, Macmahon J, Ennis M, Elborn JS. Cytokine concentrations and neutrophil elastase activity in bronchoalveolar lavage and induced sputum from patients with cystic fibrosis, mild asthma and healthy volunteers. J Cyst Fibros 2002;1:269-275.
39. Sagel SD, Kapsner R, Osberg I, Sontag MK, Accurso FJ. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001;164:1425-1431.
40. Frandsen EV, Reinholdt J, Kilian M. Immunoglobulin A1 (IgA1) proteases from Prevotella (Bacteroides) and Capnocytophaga species in relation to periodontal diseases. J Periodontal Res 1991;26:297-299.
41. Jansen HJ, Grenier D, Van der Hoeven JS. Characterization of immunoglobulin G-degrading proteases of Prevotella intermedia and Prevotella nigrescens. Oral Microbiol Immunol 1995;10:138-145.
42. Grys EL, Schade SZ, Cohen ME, Geivelis M, Robinson PJ, Simonson LG. Measurement of proteases in human subgingival dental plaque by fluorescence polarization. Arch Oral Biol 2000;45:1101-1106.
43. Handal T, Olsen I, Walker CB, Caugant DA. Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol 2004;19:303-308.
44. Brook I. Isolation of capsulate anaerobic bacteria from orofacial abscesses. J Med Microbiol 1986;22:171-174.
45. Khemaleelakul S, Baumgartner JC, Pruksakom S. Autoaggregation and coaggregation of bacteria associated with acute endodontic infections. J Endod 2006;32:312-318.
46. Diaz PI, Chalmers NI, Rickard AH, Kong C, Milburn CL, Palmer RJ Jr, Kolenbrander PE. Molecular characterization of subject-specific oral microflora during initial colonization of enamel. Appl Environ Microbiol 2006;72:2837-2848.
47. Kolenbrander PE. Oral microbial communities: biofilms, interactions, and genetic systems. Annu Rev Microbiol 2000;54:413-437.
48. Sundqvist G, Bloom GD, Enberg K, Johansson E. Phagocytosis of Bacteroides melaninogenicus and Bacteroides gingivalis in vitro by human neutrophils. J Periodontal Res 1982;17:113-121.
49. Brook I. The role of encapsulated anaerobic bacteria in synergistic infections. FEMS Microbiol Rev 1994;13:65-74.
50. Brook I. Direct and indirect pathogenicity of anaerobic bacteria in respiratory tract infections in children. Adv Pediatr 1987;34:357-377.
51. Aldridge KE. The occurrence, virulence, and antimicrobial resistance of anaerobes in polymicrobial infections. Am J Surg 1995;169:2S-7S.
52. Nord CE. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria. Clin Infect Dis 1996;23:S15-S18.
53. Olsen I, Solberg CO, Finegold SM. A primer on anaerobic bacteria and anaerobic infections for the uninitiated. Infection 1999;27:159-165.
54. Fang H, Edlund C, Hedberg M, Nord CE. New findings in beta-lactam and metronidazole resistant Bacteroides fragilis group. Int J Antimicrob Agents 2002;19:361-370.
55. Blumer JL, Saiman L, Konstan MW, Melnick D. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005;128:2336-2346.